ArticleCureus2025
Ten Years in Remission: The Long-Term Journey of a Breast Cancer Survivor.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Metastatic breast cancer (MBC) remains a challenging clinical entity, with long-term remission being rare. We report the case of a 51-year-old woman diagnosed in 2009 with HER2-positive, hormone receptor-positive invasive carcinoma of the right breast with extensive hepatic metastases. Following multimodal treatment, including surgery, multiple lines of chemotherapy, targeted therapy, and hormonal therapy, she achieved complete remission of metastatic disease in 2016 and remained disease-free until her death in 2025. Her clinical course was later complicated by the development of a second primary gastric adenocarcinoma in 2024, as well as treatment-related hepatic toxicity. This case illustrates that, in selected patients, prolonged remission can be achieved through a multidisciplinary, personalized treatment strategy and personalized approach. At the same time, it underscores the critical importance of long-term surveillance for secondary malignancies and late treatment-related adverse effects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.